We report strong in vitro and vivo efficacy of a novel LNP-formulated siRNA targeting CTNNB1 mRNA transcript for treatment of β-catenin-mutated HCC as monotherapy in early-stage disease or in combination with ICI at late-stage disease. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.